Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Goodwill (2023 - 2025)

Indivior Pharmaceuticals has reported Goodwill over the past 3 years, most recently at $2.0 million for Q4 2025.

  • For Q4 2025, Goodwill changed 0.0% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, changed 0.0%, while the annual FY2025 figure was $2.0 million, 0.0% changed from the prior year.
  • Goodwill for Q4 2025 was $2.0 million at Indivior Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
  • Over five years, Goodwill peaked at $5.0 million in Q4 2023 and troughed at $2.0 million in Q1 2024.
  • A 3-year average of $2.5 million and a median of $2.0 million in 2024 define the central range for Goodwill.
  • Biggest five-year swings in Goodwill: tumbled 60.0% in 2024 and later changed 0.0% in 2025.
  • Year by year, Goodwill stood at $5.0 million in 2023, then tumbled by 60.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Business Quant data shows Goodwill for INDV at $2.0 million in Q4 2025, $2.0 million in Q4 2024, and $2.0 million in Q3 2024.